Key result
High to very high SCORE risk significantly predicted a higher incidence of arterial occlusive events in CML patients treated with ponatinib (74.3% vs 15.2%; HR 10.9; 95% CI 1.7-67.8; P=0.01).
Why the study?
Arterial occlusive events represent emerging complications in chronic myeloid leukemia patients treated with ponatinib.
Does the Systematic Coronary Risk Evaluation (SCORE) chart predict arterial occlusive events in adult chronic myeloid leukemia patients treated with ponatinib?
Observational (n=85)
Yes
Does the Systematic Coronary Risk Evaluation (SCORE) chart predict arterial occlusive events in adult chronic myeloid leukemia patients treated with ponatinib?
Effect estimate: HR 10.9 (95% CI 1.7-67.8)
Absolute Event Rate: 74.3% vs 15.2%
p-value: p=0.01
The SCORE chart strongly predicts arterial occlusive events in CML patients treated with ponatinib, highlighting the importance of baseline cardiovascular risk assessment in cardio-oncology.
No takes yet. Share an insight, caveat, or question.
Supports SCORE stratification before ponatinib in CML; hypothesis-generating for prospective trials on risk-guided prevention.
Caocci et al. (2019) conducted an observational in Chronic myeloid leukemia (n=85). Ponatinib vs. Low to moderate SCORE risk was evaluated on Arterial occlusive events (HR 10.9, 95% CI 1.7-67.8, p=0.01). High to very high SCORE risk significantly predicted a higher incidence of arterial occlusive events in CML patients treated with ponatinib (74.3% vs 15.2%; HR 10.9; 95% CI 1.7-67.8; P=0.01).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: